Cargando…

Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation

Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-h...

Descripción completa

Detalles Bibliográficos
Autores principales: Wada, Fumiya, Kanda, Junya, Kamijo, Kimimori, Nishikubo, Masashi, Yoshioka, Satoshi, Ishikawa, Takayuki, Ueda, Yasunori, Akasaka, Takashi, Arai, Yasuyuki, Izumi, Kiyotaka, Hirata, Hirokazu, Ikeda, Takashi, Yonezawa, Akihito, Anzai, Naoyuki, Watanabe, Mitsumasa, Imada, Kazunori, Yago, Kazuhiro, Tamura, Naoki, Itoh, Mitsuru, Masuo, Yuki, Kunitomi, Akane, Takeoka, Tomoharu, Kitano, Toshiyuki, Arima, Nobuyoshi, Hishizawa, Masakatsu, Asagoe, Kohsuke, Kondo, Tadakazu, Takaori-Kondo, Akifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469234/
https://www.ncbi.nlm.nih.gov/pubmed/37646153
http://dx.doi.org/10.1177/09636897231194497
Descripción
Sumario:Haploidentical-related donor transplantation using posttransplant cyclophosphamide (PTCy-haplo) and cord blood transplantation (CBT) are valid alternatives for patients with hematological malignancies when HLA-matched donor transplantation (MDT) is unavailable. However, the effects of graft-versus-host disease (GVHD) on outcomes after these transplants have not been fully elucidated. Therefore, we evaluated the effects of acute and chronic GVHD on transplant outcomes after PTCy-haplo transplants and compared them with CBT and MDT. We included a total of 914 adult patients with hematological malignancies in the Kyoto Stem Cell Transplantation Group registry who received PTCy-haplo (N = 120), CBT (N = 402), and MDT (N = 392), and achieved neutrophil engraftment. A multivariate analysis revealed that grade I–II acute GVHD improved of overall survival (OS) after PTCy-haplo [hazard ratio (HR) = 0.39, P = 0.018] and CBT (HR = 0.48, P < 0.001), but not after MDT (HR = 0.80, P = 0.267) compared with patients without acute GVHD. Grade I–II acute GVHD had a trend toward reducing the risk of nonrelapse mortality (NRM) after PTCy-haplo (HR = 0.13, P = 0.060) and this positive effect was significant after CBT (HR = 0.39, P = 0.003). A negative impact of grade III–IV acute GVHD on NRM was observed after CBT and MDT, but not after PTCy-haplo. Limited chronic GVHD had a positive impact on OS after CBT and MDT, but not after PTCy-haplo. In conclusion, mild acute GVHD improved outcomes after PTCy-haplo and CBT, and limited chronic GVHD improved outcomes after CBT and MDT. These data indicated that the effects of GVHD on transplant outcomes depended on transplant platforms.